July 23rd 2025
BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and improving quality of life for patients.
Fitusiran May Open Doors for Treatment of Multiple Women’s Bleeding Disorders
July 20th 2023University of Pittsburgh’s Margaret Ragni, M.D., M.P.H., discussed fitusiran, the investigational small interfering RNA (siRNA) therapeutic, with Managed Healthcare Executive and also some of the possible limitations of gene therapy for hemophilia.
Read More
FDA approves Roctavian, the First Gene Therapy for Hemophilia A
June 30th 2023The price tag of $2.9 million is typical of a new wave of gene therapies. The manufacturer, BioMarin Pharmaceutical, is offering arrangements that will link the price paid by payers to how well patients respond to the treatment.
Read More
Gene Therapies for Hemophilia: Promising But There’s Room for Improvement, Say Reviewers
May 22nd 2023How long the gene therapies for hemophilia will keep factor levels high is unclear, said the authors of a review in the Annual Review of Medicine. Patients also need to be counseled that they can receive only one adeno-associated viral (AAV) vector in their lifetime.
Read More
Academic Institutions Hold Key to Gene Therapy Price Reduction, Say Academic Experts
May 22nd 2023Nonexclusive licensing of discoveries made at academic institutions would work to lower prices, say the writers of a recent opinion piece published in the New England Journal of Medicine. CMS price negotiation under the Inflation Reduction Act will not have any immediate effect on gene therapy prices and may never have.
Read More
Gene Therapy for Hemophilia Is Becoming a Reality. Who Will Write the Checks to Pay for It?
March 27th 2023Hemgenix for hemophilia B is priced to cost $3.5 million per treatment. Roctavian for hemophilia A may be approved by the FDA in July and is likely to be priced to cost between $2 million and $3 million per treatment.
Read More
Gene Therapies for Hemophilia. Possibly Curative, Likely Ultraexpensive
September 8th 2022Three gene therapies in late-stage development are designed to supply working copies of genes that people with hemophilia are missing. They may be one-time, curative treatments, but the seven-figure price tags will be an issue.
Read More